Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Sixty-four transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) received carfilzomib (days 1, 2, 8, 9, 15, 16), 300 mg/m(2) cyclophosphamide (days 1, 8, 15), 100 mg thalidomide (days 1–28) and 40 mg dexamethasone (days 1, 8, 15, 22) in 28-day cycles (CYKLONE regimen). Carfilzomi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Haematol
Prif Awduron: Mikhael, Joseph R., Reeder, Craig B., Libby, Edward N., Costa, Luciano J., Bergsagel, P. Leif, Buadi, Francis, Mayo, Angela, Nagi Reddy, Sravan K., Gano, Katherine, Dueck, Amylou C., Stewart, A. Keith
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4521972/
https://ncbi.nlm.nih.gov/pubmed/25683772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13296
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg